Flow cytometry study:
A cd45 + blast population is present with low side scatter and represents 83% of total nucleated cells. The blasts are positive for CD33, CD117, CD34 (dim), CD38, HLA-DR, CD13 (dim and variable), CD71, CD7, CD15, CD58, cMPO, CD45, CD123 (dim to negative) and CD9 (minimal 18%); they are negative for CD11b, CD14, CD61, glycophorin A, cLysozyme, TdT, CD56, CD10, B cell and other T cell markers.
A cd45 + blast population is present with low side scatter and represents 83% of total nucleated cells. The blasts are positive for CD33, CD117, CD34 (dim), CD38, HLA-DR, CD13 (dim and variable), CD71, CD7, CD15, CD58, cMPO, CD45, CD123 (dim to negative) and CD9 (minimal 18%); they are negative for CD11b, CD14, CD61, glycophorin A, cLysozyme, TdT, CD56, CD10, B cell and other T cell markers.
Cytogeneic study:
46 XY.
Molecular study: CEBPA mutation.
Diagnosis: AML with mutated CEBPA.
46 XY.
Molecular study: CEBPA mutation.
Diagnosis: AML with mutated CEBPA.